Bajaj Healthcare Ltd

NCLT approval for Genrx acquisition

• NCLT Mumbai Bench approved Genrx acquisition on a going-concern basis.
• Order dated October 13, 2026; available on NCLT website.
• Genrx to become a wholly owned subsidiary on implementation of terms.
• Order effective from October 13, 2026 until further order(s).
• Company to implement terms of the NCLT order.

Trading window and Form A disclosures

• Trading window remains closed for Designated Persons and their immediate relatives.
• Form A confirms the NCLT-related communication and effective date.
• No penalties or non-compliances identified in the communication.

Meeting Details

• Date and time: 19 October 2026 at 5:00 PM IST.
• Mode: virtual earnings call (group).
• Event: Earnings call to discuss Q2 & H1 FY27.
• Dial-in details provided for the virtual call.

Participants

• Represented by Managing Director and Chief Financial Officer.

Purpose

• Discuss Q2 and H1 FY27 financial performance.

Bajaj Healthcare Limited: Trading Window closed from Thursday, October 01, 2026 till the expiry of 48 hours after the declaration of the Un-audited Financial Results for the quarter and half year ended September 30, 2026

AGM Details

• AGM held on 21 Sep 2026 at 3:00 PM IST via VC/OAVM.
• Meeting ended at 3:34 PM.
• Record date: 14 Sep 2026; total shareholders on record: 41,967.
• Six resolutions approved by requisite majority.

Resolutions and outcomes

• Adopt Audited Financial Statements for year ended 31 March 2026 – Ordinary – Passed.
• Declare final dividend of Rs 1.50 per equity share – Ordinary – Passed.
• Re-appoint by rotation a director – Ordinary – Passed.
• Special: appoint Independent Director upon attaining age 75 – Passed.
• Remuneration payable to Non-Executive Independent Director for FY2026-27 – Special – Passed.
• Ratification of remuneration payable to Cost Auditor for FY2026-27 – Ordinary – Passed.

AGM Details

• AGM held on Monday, 21 September 2026 at 3:00 PM IST.
• Mode: VC/OAVM; meeting concluded at 3:34 PM IST.
• Quorum: 49 members attended.
• Remote e-voting window: Sep 17–20, 2026.

Resolutions

• Ordinary: Adopt audited financial statements for year ended 31 March 2026.
• Ordinary: Declare final dividend of ₹1.50 per equity share.
• Ordinary: Re-appoint Pakshal Anil Jain, retiring by rotation.
• Special: Continue Gopalakrishnan Kesavan as Non-Executive Independent Director beyond age 75.
• Special: Approve remuneration payable to Sandeep Shah for FY2026-27.
• Ordinary: Ratify remuneration payable to Cost Auditor for FY2026-27.

Director Changes

• Re-appointment of Pakshal Anil Jain (DIN: 08776385) under rotation.
• Continuation of Gopalakrishnan Kesavan as Non-Executive Independent Director on turning 75.

Key details

• Final dividend entitlement for FY2025-26, subject to AGM approval.
• Security: equity shares.
• Record date: 14 September 2026.
• Dividend amount: 30% i.e. ₹1.50 per equity share.
• Payment to shareholders on the record date if the dividend is declared and approved.

AGM Details

• 33rd AGM on 21 September 2026 at 3:00 PM IST via VC/OAVM.

Annual Report Access

• Web-link to Annual Report 2025-26 provided for shareholders without registered emails.

Email Update Cut-off

• Cut-off date for email address update is 21 August 2026.

Shareholder Reminders

• Encourages updating KYC, PAN, nomination, and contact details for online access.

Overview and scope

• Subject: BRSR FY2025-26 submitted; standalone basis, not consolidated.
• BRSR available on BajajHealth.com; forms part of the Annual Report.
• No external assurance obtained for the current year.

Key ESG metrics and governance indicators

• Export turnover ~31% of total FY25-26 turnover.
• Total energy: 501,706 GJ; renewables 3,562 GJ; non-renewables 498,144.
• Scope 1 emissions: 36,971 t CO2e; Scope 2: 12,940 t CO2e.
• Emissions intensity: 0.00000817 per turnover; PPP-adjusted 0.0001686.
• Water intensity per turnover: 0.0000329957; PPP 0.0006811.
• Waste: total 3,794 t; hazardous 3,767.55 t; incineration 1,496.36 t; landfilling 1,077.36 t.
• Governance: Board female representation 30%; KMP female 33.3%; board-approved policies.

Financial performance

• Revenue from operations ₹61,103.14 Lakh; up 12.6% YoY.
• EBITDA ₹11,195.17 Lakh; margin ~18.3%.
• PBT before exceptional items ₹6,216.96 Lakh; +35.1% YoY.
• PAT (continuing) ₹2,131.04 Lakh; total PAT ₹1,576.61 Lakh.
• Net worth ₹533 Cr; debt-equity 0.47x.
• Cash and cash equivalents ₹37.24 Cr; strong liquidity.
• Equity capital ₹16.83 Cr after warrant conversion; 3,36,62,661 shares.

Operations and capacity

• API capacity 824 MT per month; Finished DOS 100 million pieces per month.
• API and Intermediates accounted for 83% of revenue.
• Products in 60+ countries; over 250 products.
• Employees: 1,019; facilities across Gujarat and Maharashtra.
• Export turnover accounted for 31% of total revenue.

Strategic developments

• Genrx acquisition completed April 2025; Nashik facility pending tribunal approvals; not consolidated.
• Cenobamate program progressing; integrates API chemistry with formulation development.

Capital allocation and funding

• Warrant conversion raised ₹52.71 Cr; ₹17.57 Cr upfront received in 2025.
• Capital expenditure earmarked ₹35 Cr for future capacity/build-out.
• Final dividend proposed ₹1.50 per equity share (30% of face value).

Regulatory and governance

• Statutory auditor: Walker Chandiok; Secretarial auditor: Haresh Sanghvi; opinions unqualified.
• 6 Board meetings held in FY25-26; multiple director/KMP changes.
• DMFs filed: 110; governance disclosures as per BRSR.

CSR and ESG

• CSR expenditure ₹94.46 Lakh; 2% of average net profits required.
• Excess CSR carry-forward ₹89.51 Lakh; carry-forward usable per policy.

Risk and outlook

• Exports and regulatory readiness drive growth; pipeline for new APIs/formulations.
• Patent expiries provide opportunities; ongoing focus on quality/regulatory excellence.
• Regulatory/compliance, supply chain, and energy efficiency remain priorities.

Audits and internal controls

• Internal controls adequate; no material weaknesses reported.
• Internal audit: JCR & Co engaged for 2026-27; six-monthly updates to Audit Committee.
• Secretarial compliance: MR-3 Annexure I; Annexure II secretarial compliance report.